183 related articles for article (PubMed ID: 25557261)
1. Active and passive surveillance of enoxaparin generics: a case study relevant to biosimilars.
Grampp G; Bonafede M; Felix T; Li E; Malecki M; Sprafka JM
Expert Opin Drug Saf; 2015 Mar; 14(3):349-60. PubMed ID: 25557261
[TBL] [Abstract][Full Text] [Related]
2. Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.
Chao J; Skup M; Alexander E; Tundia N; Macaulay D; Wu E; Mulani P
Adv Ther; 2015 Mar; 32(3):270-83. PubMed ID: 25772256
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars of low molecular weight heparins: Relevant background information for your drug formulary.
Brouwers JRBJ; Roeters van Lennep JE; Beinema MJ
Br J Clin Pharmacol; 2019 Nov; 85(11):2479-2486. PubMed ID: 31378961
[TBL] [Abstract][Full Text] [Related]
4. An open label, non-randomized, prospective clinical trial evaluating the immunogenicity of branded enoxaparin versus biosimilars in healthy volunteers.
Gomes M; Ramacciotti E; Hoppensteadt D; Walenga JM; Lewis B; Thethi I; Fareed J
Clin Appl Thromb Hemost; 2011 Feb; 17(1):66-9. PubMed ID: 21220365
[TBL] [Abstract][Full Text] [Related]
5. Recurrent life-threatening deep tissue hematomas after switching to generic enoxaparin: a report and perspective on the approval process for biological compounds.
Kaffenberger BH; Bekaii-Saab T
Clin Appl Thromb Hemost; 2012; 18(1):104-6. PubMed ID: 21873360
[TBL] [Abstract][Full Text] [Related]
6. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
[TBL] [Abstract][Full Text] [Related]
7. [Adverse events related to substitution of generic products in Norway 2005].
Reppe LA; Stenberg-Nilsen H; Harg P; Hegge AB; Lillefloth AK; Buajordet I
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2696-700. PubMed ID: 19079413
[TBL] [Abstract][Full Text] [Related]
8. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
Niazi SK
J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
[TBL] [Abstract][Full Text] [Related]
9. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
[TBL] [Abstract][Full Text] [Related]
10. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
Hernandez I; Gellad WF
J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
[TBL] [Abstract][Full Text] [Related]
11. Structure and haemostatic effects of generic versions of enoxaparin available for clinical use in Brazil: similarity to the original drug.
Glauser BF; Vairo BC; Oliveira SN; Cinelli LP; Pereira MS; Mourão PA
Thromb Haemost; 2012 Feb; 107(2):302-14. PubMed ID: 22234635
[TBL] [Abstract][Full Text] [Related]
12. Pharmacovigilance Considerations for Biosimilars in the USA.
Grampp G; Felix T
BioDrugs; 2015 Oct; 29(5):309-21. PubMed ID: 26419971
[TBL] [Abstract][Full Text] [Related]
13. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
14. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
Stergiopoulos S; Getz K
Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular-weight heparin biosimilars: potential implications for clinical practice. Australian Low-Molecular-Weight Heparin Biosimilar Working Group (ALBW).
Nandurkar H; Chong B; Salem H; Gallus A; Ferro V; McKinnon R;
Intern Med J; 2014 May; 44(5):497-500. PubMed ID: 24816308
[TBL] [Abstract][Full Text] [Related]
16. Lower Proportion of Spontaneous Adverse Event Reports for Generic Drugs by Comparison With Original Branded Drugs at the Postmarket Stage in Japan.
Takami A; Hirata K; Ishiguro C; Hanaoka H; Uyama Y
Clin Pharmacol Ther; 2019 Jun; 105(6):1471-1476. PubMed ID: 30588617
[TBL] [Abstract][Full Text] [Related]
17. Brand vs generic adverse event reporting patterns: An authorized generic-controlled evaluation of cardiovascular medications.
Alatawi Y; Rahman MM; Cheng N; Qian J; Peissig PL; Berg RL; Page CD; Hansen RA
J Clin Pharm Ther; 2018 Jun; 43(3):327-335. PubMed ID: 29092097
[TBL] [Abstract][Full Text] [Related]
18. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA; Humphries JE; Crean S; Reynolds MW
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: a prospective randomized pilot trial.
Assadian A; Knöbl P; Hübl W; Senekowitsch C; Klingler A; Pfaffelmeyer N; Hagmüller GW
J Vasc Surg; 2008 Mar; 47(3):537-42. PubMed ID: 18234466
[TBL] [Abstract][Full Text] [Related]
20. [Biosimilars].
Krämer I
Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
